ph 22o

Sloppy New Zealand give Sam Cane and TJ Perenara winning send-off against ItalyGovt appoints Waheed Ahmed as PCSIR council member KARACHI: The federal government has appointed Waheed Ahmed, the patron-in-chief of the Pakistan Fruit and Vegetable Association (PFVA) and director of Iftekhar Ahmed and Co, as a member of the Pakistan Council of Scientific and Industrial Research (PCSIR) Council. This appointment highlights Ahmed’s vast expertise and experience in the horticulture and value-added agriculture sectors. The PCSIR council, which includes experts, government officials and industry representatives, aims to drive knowledge-based economic growth through scientific research, innovation and industrial development via public-private partnerships. The council’s initiatives will focus on promoting advanced technologies, boosting industrial competitiveness and fostering economic progress.Davion Cherwin rushed for 161 yards on 11 carries and scored two times for Drake. Jun Ahn and Luke Woodson also had rushing scores. Cherwin scored a 91-yard touchdown, the longest run in the PFL this season, to make it 21-7 early in the second quarter. Kemani Wilson made a diving interception at the Drake 25-yard line with just over two minutes left in the first half and seven plays later, Bailey found Hunter Johnson for a 24-yard touchdown to make it 28-10 at halftime. Drake defensive lineman Finn Claypool forced a fumble on the third play of the second half and his teammate recovered it. Then Bailey lofted a pass to Jaxon Laminack for a touchdown and a 35-10 lead. Drake (8-2, 7-1) was coming off a 29-20 loss to Morehead State to end a 17-game PFL winning streak — the longest active conference winning streak in the FCS. Stetson (2-9, 0-7) quarterback Brady Meitz was intercepted three times and Matt O’Connor had one of his four pass attempts intercepted. Get poll alerts and updates on the AP Top 25 throughout the season. Sign up here . AP college football: https://apnews.com/hub/ap-top-25-college-football-poll and https://apnews.com/hub/college-football

Google Says Don't Underestimate MeDeion Sanders Has Everything He Needs to Thrive in Colorado

The Canadian dollar CADUSD steadied against the U.S. dollar on Monday, clawing back its earlier declines, as investors weighed domestic GDP data as well as minutes from the Bank of Canada’s latest meeting that showed some members favoured a smaller rate cut. The loonie was trading nearly unchanged at 1.4375 per U.S. dollar, or 69.57 U.S. cents, after trading in a range of 1.4350 to 1.4433. The Bank of Canada’s decision to cut rates by 50 basis points on Dec. 11 was a close call, with some members of the governing council suggesting a 25-basis-point cut was more appropriate, the minutes showed. “We continue to expect Canadian central bankers to cut rates by another 25 basis points in January and then pause in March to assess how the economy responds to lower interest rates,” Tiago Figueiredo, a macro strategist at Desjardins, said in a note. Investors are pricing in roughly 13 basis points of easing at the central bank’s next policy decision on Jan. 29, equivalent to a 52 per cent chance of a 25-basis-point cut. Canada’s economy exceeded market expectations with 0.3 per cent growth in October, led by increases in oil and gas extraction and manufacturing, but gross domestic product likely contracted in November. On Thursday, the loonie touched its weakest intraday level since March 2020 at 1.4467. It has had to contend recently with the threat of U.S. trade tariffs as well as a hawkish shift by the Federal Reserve and domestic political uncertainty. Canadian Prime Minister Justin Trudeau is under increasing pressure from his own legislators to step down and let someone else take over. The U.S. dollar resumed its upward trajectory against a basket of major currencies as U.S. Treasury yields climbed. The Canadian 10-year yield was up 1.8 basis points at 3.295 per cent.Tioga-Sequoia Brewing Company Instagram photo Tioga-Sequoia Beer Garden was already one of Fresno’s most well-known locations. Now, with the popular beer garden being included in the official Fresno edition of Monopoly, even more people will become exposed to Tioga-Sequoia. On Nov. 22, Tioga-Sequoia celebrated its participation in the famous board game with a launch party. Tioga-Sequoia’s president Michael Cruz said that they were the first business featured in Fresno Monopoly to sell physical copies of the game and sold over 40 boards during the launch party. Cruz had been anticipating being selected for Monopoly for months, and they were still excited when they found out they had been chosen. Visit Fresno County, the county’s visitor’s bureau, recommended Tioga-Sequoia. “[Monopoly] was referred to us by the visitor’s bureau,” Cruz said. “They worked with local entities to kind of see who the icons in the valley are within different segments that they can appeal to and interview for the board, and I believe that’s how we got on their radar.” Cruz touched on what being a part of the game meant for him and the company. “They only do one [Fresno Monopoly version], so to be on something, one version of the first and only version of something that memorializes our place in the city. It’s more than just the immediate press that you get off of it,” Cruz said. “It’s something that’s going to be ingrained in a board game that people are familiar with, and they’ll be even more familiar with this local version that appeals to them and brings back memories and experiences.” One of the biggest storylines heading into 2025 for Fresno Tioga-Sequoia Beer Garden was already one of Fresno’s most well-known The Madera County Department of Public Health announced Monday that Dr. Rolston St. Hilaire, dean of the Jordan College of Agricultural

Storm Bert: The moment flood sirens sound off in Yorkshire market townNewly-elected Independent Shivaji Patil, women injured in fire during victory celebrations

NoneBARCELONA – Tens of thousands of Spaniards marched in downtown Barcelona on Saturday to protest the skyrocketing cost of renting an apartment in the popular tourist destination. Protesters cut off traffic on main avenues in the city center, holding up homemade signs in Spanish reading “Fewer apartments for investing and more homes for living" and “The people without homes uphold their rights.” Recommended Videos The lack of affordable housing has become one of the leading concerns for the southern European Union country, mirroring the housing crunch across many parts of the world, including the United States . Organizers said that over 100,000 had turned out, while Barcelona’s police said they estimated some 22,000 marched. Either way, the throngs of people clogging the streets recalled the massive separatist rallies at the heigh of the previous decade’s Catalan independence movement. Now, social concerns led by housing have displaced political crusades. That is because the average rent for Spain has doubled in last 10 years. The price per square meter has risen from 7.2 euros ($7.5) in 2014 to 13 euros this year, according to the popular online real estate website Idealista. The growth is even more acute in cities like Barcelona and Madrid. Incomes meanwhile have failed to keep up, especially for younger people in a country with chronically high unemployment. Protestor Samuel Saintot said he is “frustrated and scared” after being told by the owners of the apartment he has rented for the past 15 years in Barcelona’s city center that he must vacate the premises. He suspects that the owners want him out so they can renovate it and boost the price. “Even looking in a 20- or 30-kilometer radius outside town, I can’t even find anything within the price range I can afford,” he told The Associated Press. “And I consider myself a very fortunate person, because I earn a decent salary. And even in my case, I may be forced to leave town.” A report by the Bank of Spain indicates that nearly 40% of Spaniards who rent dedicate an average of 40% of their income to paying rents and utilities, compared to the European Union average of 27% of renters who do so. “We are talking about a housing emergency. It means people having many difficulties both in accessing and staying in their homes,” said Ignasi Martí, professor for Esade business school and head of its Dignified Housing Observatory. The rise in rents is causing significant pain in Spain, where traditionally people seek to own their homes. Rental prices have also been driven up by short-term renters including tourists. Many migrants to Spain are also disproportionately hit by the high rents because they often do not have enough savings. Spain is near the bottom end of OECD countries with under 2% of all housing available being public housing for rent. The OECD average is 7%. Spain is far behind France, with 14%, Britain with 16%, and the Netherlands with 34%. Carme Arcarazo, spokesperson for Barcelona’s Tenants Union which helped organize the protest, said that renters should consider a “rent strike” and cease paying their monthly rents in a mass protest movement. “I think we the tenants have understood that this depends on us. That we can’t keep asking and making demands to the authorities and waiting for an answer. We must take the reins of the situation,” Arcarazo told the AP. “So, if they (the owners) won’t lower the rent, then we will force them to do it." The Barcelona protest came a month after tens of thousands rallied against high rents in Madrid. The rising discontent over housing is putting pressure on Spain’s governing Socialist party, which leads a coalition on the national level and is in charge of Catalonia’s regional government and Barcelona’s city hall. Spanish Prime Minister Pedro Sánchez presided over what the government termed a “housing summit” including government officials and real estate developers last month. But the Barcelona’s Tenants Union boycotted the event, saying it was like calling a summit for curing cancer and inviting tobacco companies to participate. The leading government measure has been a rent cap mechanism that the central government has offered to regional authorities based on a price index established by the housing ministry. Rent controls can be applied to areas deemed to be “highly stressed” by high rental prices. Catalonia was the first region to apply those caps, which are in place in downtown Barcelona. Many locals blame the million of tourists who visit Barcelona, and the rest of Spain, each year for the high prices. Barcelona’s town hall has pledged to completely eliminate the city’s 10,000 so called “tourist apartments,” or dwellings with permits for short-term rents, by 2028.IRVINE, Calif., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp. (NASDAQ: OCX), a diagnostics technology company, today announced the publication of favorable data regarding its DetermaCNITM assay. In a paper recently published in the journal Acta Neuropathologica Communications, DetermaCNI showed promise as a liquid biopsy method for diagnosing and profiling central nervous system tumors by measuring somatic copy number aberrations (SCNAs) in cerebrospinal fluid. For context, copy number instability (CNI) is a scientifically well-known hallmark of cancer. DetermaCNITM is a patented approach to measuring CNI for the diagnosis and monitoring of cancer. Nearly 300,000 patients in the U.S. each year face primary brain tumors or brain metastasis 1 . The current standard of care for the confirmation and classification of brain tumors often involves high-risk, highly invasive biopsy of brain tissue. Thus, a liquid biopsy method for diagnosing brain tumors could offer significant benefits over currently available methods, representing a potential $300 million U.S. market opportunity. Among the study authors were Oncocyte Chief Science Officer Ekke Schuetz and Senior R&D Director Julia Beck. "This was a proof of principle study to assess whether copy number instability could be measured in the cerebrospinal fluid of patients with brain cancer. The findings suggest that a significant number of the nearly 300,000 patients diagnosed with brain tumors every year in the U.S. could benefit from DetermaCNI,” Dr. Schuetz said. "We congratulate the research team in Frankfurt on the publication of this study in an area of high unmet need.” As noted in the paper, the gold standard for precise diagnostic classification of brain tumors requires a biopsy, with risks including limited sensitivity and failing to measure the diverse potential regions of the tumor. SCNAs were observed in the cerebrospinal fluid of ten out of the 12 patients with confirmed central nervous system cancers. SCNAs were not observed in any of the 11 patients with benign or unclear central nervous system lesions. The detection of SCNAs is highly specific for tumor-derived cell-free DNA (cfDNA). Overall, this new study demonstrates DetermaCNI's potential for providing a molecularly informed diagnosis of central nervous system cancers, mapping tumor heterogeneity, tracking tumor evolution, and surveilling tumor patients through a liquid biopsy of cerebrospinal fluid. Oncocyte believes this study validates the future clinical potential for DetermaCNI, as well as the direction of the company's research and development pipeline, which is designed to drive sustained rapid growth over the next decade. Oncocyte's mission is to democratize access to molecular diagnostic testing to improve patient outcomes. The company is investing in developing products to serve the separate verticals of organ transplant testing and oncology. Oncocyte is presently commercializing its transplant product line, which includes the VitaGraftTM and GraftAssureTM tests. It expects to commercialize its oncology assays over the next two years. _______________ 1 "Brain Metastases.” MD Anderson Cancer Center , www.mdanderson.org/cancer-types/brain-metastases.html. And "Brain Tumor Facts.” National Brain Tumor Society , 20 Feb. 2024, braintumor.org/brain-tumors/about-brain-tumors/brain-tumor-facts/. About Oncocyte Oncocyte is a diagnostics technology company. The Company's tests are designed to help provide clarity and confidence to physicians and their patients. VitaGraftTM is a clinical blood-based dd-cfDNA solid organ transplantation monitoring test. GraftAssureTM is a research use only (RUO) blood-based solid dd-cfDNA organ transplantation monitoring test kit for decentralized use. DetermaIOTM is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. DetermaCNITM is a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients. For more information about Oncocyte, please visit https://oncocyte.com/ . For more information about our products, please visit the following web pages: VitaGraft KidneyTM - https://oncocyte.com/vitagraft-kidney/ VitaGraft Liver TM - https://oncocyte.com/vitagraft-liver/ GraftAssureTM - https://oncocyte.com/graftassure/ DetermaIOTM - https://oncocyte.com/determa-io/ DetermaCNITM - https://oncocyte.com/determa-cni/ VitaGraftTM, GraftAssureTM, DetermaIOTM, and DetermaCNITM are trademarks of Oncocyte Corporation. CONTACT: Jeff Ramson PCG Advisory (646) 863-6893 [email protected] Forward-Looking Statements Any statements that are not historical fact (including, but not limited to statements that contain words such as "will,” "believes,” "plans,” "anticipates,” "expects,” "estimates,” "may,” and similar expressions) are forward-looking statements. These statements include those pertaining to, among other things, the belief that the new study validates the future clinical potential for DetermaCNI, as well as the direction of the company's research and development pipeline, the expectation that Oncocyte will commercialize its oncology assays over the next two years, and other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of diagnostic tests or products, uncertainty in the results of clinical trials or regulatory approvals, the capacity of Oncocyte's third-party supplied blood sample analytic system to provide consistent and precise analytic results on a commercial scale, potential interruptions to supply chains, the need and ability to obtain future capital, maintenance of intellectual property rights in all applicable jurisdictions, obligations to third parties with respect to licensed or acquired technology and products, the need to obtain third party reimbursement for patients' use of any diagnostic tests Oncocyte or its subsidiaries commercialize in applicable jurisdictions, and risks inherent in strategic transactions such as the potential failure to realize anticipated benefits, legal, regulatory or political changes in the applicable jurisdictions, accounting and quality controls, potential greater than estimated allocations of resources to develop and commercialize technologies, or potential failure to maintain any laboratory accreditation or certification. Actual results may differ materially from the results anticipated in these forward-looking statements and accordingly such statements should be evaluated together with the many uncertainties that affect the business of Oncocyte, particularly those mentioned in the "Risk Factors” and other cautionary statements found in Oncocyte's Securities and Exchange Commission (SEC) filings, which are available from the SEC's website. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Oncocyte undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.